Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
300 articles
A global consortium reveals how tube type, delays, and storage temperature dramatically skew key Alzheimer's blood biomarker readings.
A novel Aβ1-10 peptide vaccine conjugated to carrier proteins reduced plaques, neuroinflammation, and memory deficits in an AD mouse model.
New review links HCMV — infecting up to 100% of adults — to Alzheimer's pathology, tau tangles, and accelerated cognitive decline.
New research reveals APOE2, the longevity-linked gene variant, shields human neurons from aging damage through enhanced DNA repair — not just lipid metabolism.
A 38-year Finnish cohort study finds higher lifelong physical activity protects information processing and working memory into midlife.
A completed pilot trial tested humanoid robots and AI predictive models to manage dementia care at home, personalizing treatment pathways.
New iPSC and cerebral organoid research shows HSV-1 directly activates neurodegeneration and senescence pathways, supporting the viral hypothesis of Alzheimer's disease.
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
A phase 2 RCT finds ABvac40, a vaccine targeting vascular amyloid-β40, is safe and immunogenic in early Alzheimer's patients with no ARIA-E.
β-endorphin released during exercise wraps around toxic Aβ aggregates, forming a 'corona' that shields brain cells from Alzheimer's damage.
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
